"1" . . "[FC70E99F927B]" . . "\u0160pi\u010Dka, I." . . . . . "proteasome; proteasome inhibitors; histone deacetylase inhibitors; leukemia; apoptosis"@en . . . "16"^^ . "P(NR9045), V, Z(MZ0UHKT2005)" . "RIV/00023736:_____/09:00008279!RIV10-MZ0-00023736" . . "4"^^ . "Fuchs, Ota" . . "1871-529X" . "9" . "Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells" . . . "NL - Nizozemsko" . "Marinov, Iuri" . . "RIV/00023736:_____/09:00008279" . . "303524" . . . . . "Provazn\u00EDkov\u00E1, Dana" . "Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells" . "Ku\u017Eelov\u00E1, Kate\u0159ina" . "Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells"@en . . "Cardiovascular & Hematological Disorders : Drug Targets" . . "Marinov, Iuri" . "Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells"@en . "Proteasome inhibition is considered as novel treatment strategy in leukemia. We studied the effect of bortezomib (10 nM) on DNA synthesis and apoptosis in human acute myeloid cell lines KASUMI-1, ML-1, ML-2 and CTV-1 cells. Bortezomib was potent inhibitor of DNA synthesisin all four types of leukemia cells but not in ML-1 cells. Proteasome inhibition as monotherapy and its combination with histone deacetylase inhibitors and with conventional therapies is promising because malignant cells are more sensitive to this treatment than normal hematopoietic cells."@en . "Proteasome inhibition is considered as novel treatment strategy in leukemia. We studied the effect of bortezomib (10 nM) on DNA synthesis and apoptosis in human acute myeloid cell lines KASUMI-1, ML-1, ML-2 and CTV-1 cells. Bortezomib was potent inhibitor of DNA synthesisin all four types of leukemia cells but not in ML-1 cells. Proteasome inhibition as monotherapy and its combination with histone deacetylase inhibitors and with conventional therapies is promising because malignant cells are more sensitive to this treatment than normal hematopoietic cells." . . "5"^^ . .